Brain & Mental Health Laboratory, School of Psychological Sciences & Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Clayton, VIC, 3168, Australia.
Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
Transl Psychiatry. 2018 Mar 6;8(1):59. doi: 10.1038/s41398-018-0108-8.
Mood disturbances seen in first-episode mania (FEM) are linked to disturbed functional connectivity of the striatum. Lithium and quetiapine are effective treatments for mania but their neurobiological effects remain largely unknown. We conducted a single-blinded randomized controlled maintenance trial in 61 FEM patients and 30 healthy controls. Patients were stabilized for a minimum of 2 weeks on lithium plus quetiapine then randomly assigned to either lithium (serum level 0.6 mmol/L) or quetiapine (dosed up to 800 mg/day) treatment for 12 months. Resting-state fMRI was acquired at baseline, 3 months (patient only) and 12 months. The effects of treatment group, time and their interaction, on striatal functional connectivity were assessed using voxel-wise general linear modelling. At baseline, FEM patients showed reduced connectivity in the dorsal (p = 0.05) and caudal (p = 0.008) cortico-striatal systems when compared to healthy controls at baseline. FEM patients also showed increased connectivity in a circuit linking the ventral striatum with the medial orbitofrontal cortex, cerebellum and thalamus (p = 0.02). Longitudinally, we found a significant interaction between time and treatment group, such that lithium was more rapid, compared to quetiapine, in normalizing abnormally increased functional connectivity, as assessed at 3-month and 12-month follow-ups. The results suggest that FEM is associated with reduced connectivity in dorsal and caudal corticostriatal systems, as well as increased functional connectivity of ventral striatal systems. Lithium appears to act more rapidly than quetiapine in normalizing hyperconnectivity of the ventral striatum with the cerebellum. The study was registered on the Australian and New Zealand Clinical Trials Registry (ACTRN12607000639426). http://www.anzctr.org.au.
首发躁狂症(FEM)中观察到的情绪障碍与纹状体功能连接障碍有关。锂和喹硫平是治疗躁狂症的有效方法,但它们的神经生物学作用仍知之甚少。我们在 61 名首发躁狂症患者和 30 名健康对照者中进行了一项单盲随机对照维持试验。患者在锂加喹硫平稳定至少 2 周后,随机分为锂(血清水平 0.6mmol/L)或喹硫平(剂量高达 800mg/天)治疗 12 个月。在基线、3 个月(仅患者)和 12 个月采集静息态 fMRI。使用体素水平的一般线性模型评估治疗组、时间及其相互作用对纹状体功能连接的影响。在基线时,与基线时的健康对照组相比,FEM 患者的背侧(p=0.05)和尾侧(p=0.008)皮质纹状体系统的连接减少。FEM 患者还显示出与腹侧纹状体与内侧眶额皮质、小脑和丘脑相连的回路连接增加(p=0.02)。纵向研究发现,时间和治疗组之间存在显著的相互作用,即与喹硫平相比,锂在 3 个月和 12 个月的随访中更快地使异常增加的功能连接正常化。结果表明,FEM 与背侧和尾侧皮质纹状体系统的连接减少以及腹侧纹状体系统的功能连接增加有关。锂似乎比喹硫平更快地使小脑腹侧纹状体的超连接正常化。该研究已在澳大利亚和新西兰临床试验注册中心(ACTRN12607000639426)注册。http://www.anzctr.org.au。